Poster Presentation on Molecular Targets and Cancer Therapeutics Conference
The PamGene technology plays a central role in a study of Dr Anne Hansen Ree et al., which she presented during the Molecular Targets and Cancer Therapeutics Conference in San Francisco, from November 12-16. The study examined to which degree kinase activity in tumours might reflect mutations of certain genes.


Group of interest are patients with metastatic colorectal cancer that are resistance to anti-EGFR antibody therapeutics. The resistance is correlated to tumour mutations within specific genes (KRAS, BRAF and PIK3CA). The question is whether analysis of tyrosine kinase activity can help to predict whether a patient will successfully respond to anti-EGFR antibody treatment.
The researchers took primary tumour samples from 63 patients with locally advanced rectal cancer and analysed the mutation of the specific genes. After that they performed profiling of tumour tyrosine kinase activity on PamChip arrays.
The conclusion of the study is that tyrosine kinase activity may provide information on EGFR signalling pathway druggability.
Read the abstract: Ex vivo kinome profiling of tumors from rectal cancer patients for possible identification of functional biomarkers of EGFR signaling pathway druggability.
Download the poster presentation here.